This “Heads We Win, Tails We Still Win” Pharmaceutical Distributor Stock Is “Incredibly Cheap”

In regards to the stock of this high-quality pharmaceutical distributor, the author of today’s article declares that it “is not just cheap – it’s incredibly cheap.” But what about concerns the market currently has about this stock – namely Amazon’s entrance into the drug distribution space and White House rhetoric on drug prices? The author lays out how, under even the worst-case scenario for this company, it’s a “heads we win, tails we get less, but we still win” scenario for investors. For more, CLICK HERE.

These Beaten-Down Biotechs’ Pipelines Are Available For Practically Free

“You don’t usually get the chance to pick up the entire research-and-development arm of a major company for free,” acknowledges the author of today’s article – but he proceeds to highlight how, in the aftermath of the stock market rout, shares of some biotech companies have been pushed down to the point where investors get those companies’ pipelines “just about for free.” For two such biotechs – as well as a third which may still be a good deal despite having rebounded – CLICK HERE.